Andrés Jiménez-Zúñiga

Andrés Jiménez-Zúñiga

Auto-generated profile, based on publicly available information

Andrés Jiménez-Zúñiga

Neurosciences Area, Biogipuzkoa Health Research Institute, Donostia/San Sebastián 20014, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2024 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
MZMónica Zufiría
Mónica Zufiría
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
MGMaddi Garciandia-Arcelus
Maddi Garciandia-Arcelus
XBXabier Bengoetxea
Xabier Bengoetxea
AJAndrés Jiménez
Andrés Jiménez
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS. We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS-silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

3 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AJAndrés Jiménez-Zúñiga
Andrés Jiménez-Zúñiga
GFGorka Fernández-Eulate
Gorka Fernández-Eulate
JRJosé I. Ruíz-Sanz
José I. Ruíz-Sanz
JZJose Luis Zúñiga-Elizari
Jose Luis Zúñiga-Elizari
MGMaddi Garciandia
Maddi Garciandia
FGFrancisco Gil-Bea
Francisco Gil-Bea
Background: Amyotrophic lateral sclerosis (ALS) is characterized by profound metabolic reprogramming, yet the lack of biomarkers for specific druggable targets remains a major hurdle for precision medicine. We hypothesized that peripheral lipid biosynthetic signatures could serve as both prognostic indicators and a roadmap for identifying novel disease-modifying targets. Methods: We assessed serum fatty acid (FA) metabolic pathways in two independent longitudinal cohorts (n = 37 and n = 38) using high-dimensional CoxBoost modeling. Primary outcomes were survival and functional staging milestones, including non-invasive ventilation and gastrostomy. The biological relevance of the identified candidate was further assessed through correlation with plasma neurofilament light-chain (NfL) levels. Causality and therapeutic potential were validated in Drosophila melanogaster models of TDP-43 proteinopathy via genetic ablation and pharmacological inhibition. Results: Our multi-parametric model, comprising two clinical variables and the estimated ELOVL6 (elongation of very long-chain fatty acids protein 6) activity, demonstrated robust prognostic accuracy (Uno’s C 0.69) across both cohorts; ELOVL6 activity served as a strong independent predictor of mortality and functional decline. Notably, high ELOVL6 activity significantly correlated with elevated plasma NfL levels (p < 0.01), linking peripheral elongation imbalances to central axonal damage. In Drosophila, ELOVL6 overactivation was identified as a conserved pathological consequence of TDP-43 dysfunction, characterized by an increased C18:0/C16:0 ratio in both loss-of-function and gain-of-function models. Inhibition of ELOVL6, either genetically or pharmacologically, rescued neuromuscular junction integrity, prolonged survival, and significantly reduced pathological TDP-43 phosphorylation in glial models. Conclusion: These findings position ELOVL6 as a promising modifiable metabolic node with potential for disease-modifying intervention in ALS. Beyond its potential utility for identifying high-risk metabolic profiles and assisting in prognostic counseling, ELOVL6 bridges systemic lipid dysregulation with TDP-43 proteinopathy. Targeting this pathway offers a dual opportunity: as a biological marker to supplement clinical staging and as a druggable enzymatic target to ameliorate motor neuron degeneration. HIGHLIGHTS: Systemic ELOVL6 activity is a robust independent predictor of ALS survival. High ELOVL6 levels correlate with plasma NfL and functional decline. Inhibition of ELOVL6 rescues NMJ integrity and survival in Drosophila models. Pharmacological targeting of ELOVL6 reduces glial TDP-43 phosphorylation. ELOVL6 represents a druggable metabolic node linking lipids to proteinopathy.

17 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MZMónica Zufiría
Mónica Zufiría
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
MGMaddi Garciandia-Arcelus
Maddi Garciandia-Arcelus
XBXabier Bengoetxea
Xabier Bengoetxea
AJAndrés Jiménez
Andrés Jiménez
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS . We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs ( TBPH or caz ) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

18 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AJAndrés Jiménez-Zúñiga
Andrés Jiménez-Zúñiga
AAAlex M. Ascensión
Alex M. Ascensión
ASAngela Sanchez-Molleda
Angela Sanchez-Molleda
IJIrene Jiménez-Salvador
Irene Jiménez-Salvador
MLMartín Fuentetaja Leza
Martín Fuentetaja Leza
GGGorka Gereñu
Gorka Gereñu
Intercellular propagation of pathological TDP-43 drives the progression of ALS and FTD, yet the mechanisms enabling transmission remain elusive. Here, we demonstrate that Activity-regulated cytoskeleton associated protein (ARC/Arg3.1) is pathologically subverted to act as a retroviral-like capsid vehicle for TDP-43 spreading. In a Drosophila model, we reveal that massive Arc1 upregulation drives glia-to-neuron TDP-43 seeding, while its genetic ablation halts pathological transfer, improves motor function, and extends survival. In parallel human cellular models, stress-induced ARC colocalizes with TDP-43 to orchestrate its intercellular transmission. Guided by ARC’s capsid architecture, we reproposed Lenacapavir, an FDA-approved HIV-1 capsid modulator, as a stable binder of ARC/Arg3.1 capsid interfaces. Lenacapavir treatment effectively blocks TDP-43 propagation in vitro and rescues disease phenotypes in vivo. Our findings establish ARC as a conserved vehicle for pathological protein transmission and deliver an immediately translatable pharmacological strategy to arrest disease progression in ALS and FTD.